Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RuxoTam
NL-OMON59288Phase 2Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of tamoxifen and ruxolitinib in myelofibrosis (MF), sponsored by University Medical Center Groningen. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
tamoxifenruxolitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NL-OMON59288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59288.